CanFite BioPharma: Funding, Investors & Team (Sep 2026)
Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.
CanFite BioPharma has raised $32.3M across 4 funding rounds on record, the most recent an undisclosed round of $4.3M announced in Mar 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CanFite BioPharma Company Profile and Key Stats
Latest funding round on record: Mar 2026.
CanFite BioPharma Funding Rounds
CanFite BioPharma raised $10.0M in a Post-IPO Equity announced in Aug 2021.
3.7 years later, an undisclosed round of $3.0M was announced in Apr 2025.
3 months later, an undisclosed round of $15.0M was announced in Jul 2025.
8 months later, an undisclosed round of $4.3M was announced in Mar 2026.
CanFite BioPharma Founders and Leadership Team
Contact details for the CanFite BioPharma team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →CanFite BioPharma Funding Compared to Other Biotechnology Startups
CanFite BioPharma's latest round of $4.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CanFite BioPharma in Biotechnology and Petah Tiqva
Companies Similar to CanFite BioPharma
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
CanFite BioPharma Funding FAQs
What does CanFite BioPharma do?
Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.
How much funding has CanFite BioPharma raised?
CanFite BioPharma has raised $32.3M across 4 rounds on record. The most recent is an undisclosed round of $4.3M announced in Mar 2026.
When did CanFite BioPharma last raise funding?
CanFite BioPharma's most recent funding round on record is an undisclosed round of $4.3M, announced in Mar 2026.
Who founded CanFite BioPharma?
FundedIQ lists Motti Farbstein (Founder), Pnina Fishman (Founder) at CanFite BioPharma.
Where is CanFite BioPharma headquartered?
CanFite BioPharma is based in Petah Tiqva, Hamerkaz, Israel.
How many employees does CanFite BioPharma have?
CanFite BioPharma is in the 1-10 employee band.
How does CanFite BioPharma's funding compare to other Biotechnology startups?
CanFite BioPharma's latest round of $4.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's CanFite BioPharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CanFite BioPharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.